Renal Protective Effects of Renin Angiotensin System (RAS) Inhibitor in Peritoneal Dialysis Patients

• Status: Completed
• Trial end date: 2014-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a multicentre study examining the effectiveness of angiotension converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB) or a combination of both in reducing the rate of decline in residual renal function (RRF) in continuous ambulatory peritoneal dialysis (CAPD) patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sun Yat-sen University
• Treatments: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benazepril; Valsartan

Criteria

Inclusion Criteria:

• All patients received CAPD more than 1 months

• Subjects of either sex, 20-75 years old

• Residual GFR of 3mL/min per 1.73 m2 or more

• With hypertension

• No history of taking an ACE inhibitor or angiotensin-receptor blockers for at least 1 month

• Provision of written informed consent by subject or guardian

Exclusion Criteria:

• Underlying medical conditions, such as congestive heart failure, or therapy with an ACE inhibitor or ARB

• Peritonitis or volume overload within the preceding 1 month

• Myocardial infarction within the preceding 6 months

• Clinically significant valvular disease

• Malignant hypertension

• History of hypertensive encephalopathy or cerebrovascular accident within the preceding 6 months

• Any condition that may have precluded a patient from remaining in the study, such as alcohol or drug abuse, chronic liver disease, malignant disease, or psychiatric disorder

• History of allergy or intolerance to an ACE inhibitor or ARB

• Participation in another clinic trial within 2 weeks prior to screening